Has the Amazon Prime of Cancer Genomic Profiling Arrived?

Posted by Pavankumar Anne on Dec 12, 2019 9:31:04 AM

Jim Adelizzi co-wrote this blog post with Pavankumar Anne.

The excitement behind precision medicine in oncology is impossible to ignore. Genomic profiling has enabled the greatest growth in precision medicine in oncology, and today there are 80-plus FDA-approved treatment options indicated for specific genetic markers. Innovations in next-generation sequencing (NGS) technology have further enabled advances in genomic profiling by increasing the speed, accuracy and affordability of sequencing. With this innovation comes a variety of options for testing:


>
Read More

CAR-T Therapies: Improving on Today’s Reality and Planning for Tomorrow’s Innovation

Posted by Sharon Karlsberg on Jul 5, 2018 8:00:00 AM

Katie Blodgett and Robert Rovner co-authored this post with Sharon Karlsberg. 

Adoptive cell immunotherapy got top billing at this year’s American Society of Clinical Oncology (ASCO) meeting with its designation as the 2018 clinical cancer “Advance of the Year,” and for good reason. The first generation of chimeric antigen receptor T-cell (CAR-T) therapies, set in motion with the late 2017 approvals of Kymriah (Novartis) and Yescarta (Kite, a Gilead company), are among the most anticipated cancer breakthroughs to date.


>
Read More

Upending the Treatment Paradigm in AML

Posted by Nathan Noll on Dec 19, 2017 9:40:13 AM

Sony introduced the Walkman in 1979. At the time, it was revolutionary, but when compared with the technology available today, it is woefully outmatched.


>
Read More

Beyond PD-L1: In Search of Better Biomarkers

Posted by Sharon Karlsberg on Jul 14, 2017 8:00:00 AM

Tyler Vogt co-wrote this blog post with Sharon Karlsberg. 

Since their first approval in 2014, PD-L1 and PD-1 checkpoint inhibitors have become the backbone therapy in multiple tumor types: melanoma, bladder cancer and non-small-cell lung cancer (NSCLC). Although only 20 to 35% of patients respond to these therapies, approvals in melanoma, bladder cancer and second-line lung cancer didn’t require an associated diagnostic test for PD-L1 status. Until the failure of BMS’s CheckMate-026 trial in first-line NSCLC, oncologists were asking the question, “Should I test for PD-L1?”


>
Read More

Showdown at the ‘IO’ Corral

Posted by Malik Kaman on Apr 5, 2017 9:00:00 AM

Checkpoint inhibitors (CPIs) and chimeric antigen receptors (CAR-Ts) have transformed the field of cancer immunotherapy over the past five years. So far, these therapeutic approaches have operated in mutually exclusive landscapes with CPIs focusing on solid tumors and CAR-Ts focusing on hematologic malignancies, but now they’re entering each other’s spaces. As PD-1/L1 therapies enter hematology, and as CAR-Ts expand into solid tumors, should we expect a showdown at the immuno-oncology corral? 


>
Read More